IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees

While the RV144 HIV vaccine trial led to moderately reduced risk of HIV acquisition, emerging data from the HVTN702 trial point to the critical need to reexamine RV144-based correlates of reduced risk of protection. While in RV144, the induction of V2-binding, non-IgA, IgG3 antibody responses with n...

全面介紹

書目詳細資料

Principais autores:	Stephanie Fischinger, Sepideh Dolatshahi, Madeleine F. Jennewein, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Nelson Michael, Sandhya Vasan, Margaret E. Ackerman, Hendrik Streeck, Galit Alter
格式:	Artigo
語言:	Inglês
出版:	American Society for Clinical investigation 2020-11-01
叢編:	JCI Insight
主題:	AIDS/HIV Vaccines
在線閱讀:	https://doi.org/10.1172/jci.insight.140925
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!